Company Information

    Apollomics was founded on January 2016. The company is based in Santa Clara, CA, USA . The number of employees in Apollomics is less than 50. Apollomics is a developer of oncology therapeutics intend to harness the immune system and targeting specific molecular pathways.

    Here is how Apollomics describes itself: "Committed to the discovery and development of oncology combination therapies"
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Apollomics has received 3 rounds of venture funding. The total funding amount is around $114.8M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Apollomics - Blog

                          • Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

                          • MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, September 30, 2021 – Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first … Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial Read More »The post Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial appeared first on Apollomics, Inc..
                          • APOLLOMICS, INC. DOSES FIRST PATIENT IN A PHASE I CLINICAL TRIAL OF APL-102

                          • Foster City, CA, Hangzhou and Shanghai, China, August 10, 2021, Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. The Phase I trial … APOLLOMICS, INC. DOSES FIRST PATIENT IN A PHASE I CLINICAL TRIAL OF APL-102 Read More »The post APOLLOMICS, INC. DOSES FIRST PATIENT IN A PHASE I CLINICAL TRIAL OF APL-102 appeared first on Apollomics, Inc..
                          • APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH

                          • Foster City, CA, Shanghai and Hangzhou, China, May 20, 2021 — Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai. Dr. Guoliang Yu, the company’s Co-Founder, … APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH Read More »The post APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH appeared first on Apollomics, Inc..
                          • Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer

                          • – Fibrogen veteran brings global R&D expertise to Management Team – – Merck KGaA Executive Sophie (Zhengjie) Sun named Senior Vice President, Corporate Development bringing partnership, strategy and commercialization expertise – Foster City, CA, and Hangzhou, China, March 9, 2021 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and … Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer Read More »The post Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer appeared first on Apollomics, Inc..
                          • APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA

                          • FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, March 4, 2021, Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed … APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA Read More »The post APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA appeared first on Apollomics, Inc..
                          • Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa

                          • TYG100 utilizes proprietary S-TIR™ technology platform enabling specific B cell and T cell responses against tumor antigens  FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, February 12, 2021 – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development … Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa Read More »The post Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa appeared first on Apollomics, Inc..

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *